We have allelotyped a series of 104 Finnish colorectal cancers (CRCs) using 372 polymorphic markers spaced, on average, at 10 cM intervals, and have made a comparison of the differences in the frequency of allelic imbalance (AI) between familial and sporadic cases. Differences in the frequency of allelic imbalance (loss of heterozygosity or amplification) at a number of loci were detected and these were evaluated through analysis of additional series of cancers using specific markers. The most consistent difference was observed at chromosome 20q13.1-13.3 characterized by a two fold difference between familial and nonfamilial disease in a total of 99 familial and 186 sporadic Finnish cases. This difference was not observed in a UK set of 67 familial and 96 sporadic CRCs. The genome-wide effort resulted in a large data set giving clues to the location of putative CRC predisposition genes in the genome. The approach provides an alternative strategy for detecting cancer predisposition genes solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families.
We have allelotyped a series of 104 Finnish colorectal cancers (CRCs) using 372 polymorphic markers spaced, on average, at 10 cM intervals, and have made a comparison of the differences in the frequency of allelic imbalance (AI) between familial and sporadic cases. Differences in the frequency of allelic imbalance (loss of heterozygosity or amplification) at a number of loci were detected and these were evaluated through analysis of additional series of cancers using specific markers. The most consistent difference was observed at chromosome 20q13.1-13.3 characterized by a two fold difference between familial and nonfamilial disease in a total of 99 familial and 186 sporadic Finnish cases. This difference was not observed in a UK set of 67 familial and 96 sporadic CRCs. The genome-wide effort resulted in a large data set giving clues to the location of putative CRC predisposition genes in the genome. The approach provides an alternative strategy for detecting cancer predisposition genes solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families. Oncogene (2003 Oncogene ( ) 22, 2206 Oncogene ( -2214 Oncogene ( . doi:10.1038 Keywords: colorectal cancer; familial; hereditary; allelic imbalance; loss of heterozygosity A recent twin study indicates that B35% of all colorectal cancer (CRC) can be ascribed to inherited genetic susceptibility (Lichtenstein et al., 2000) . However, only 2-5% can be ascribed to dominant syndromes for which mutations have been shown to be causative (Burt et al., 1990; Bonaiti-Pellie, 1999) : APC, DNA mismatch repair (MMR) genes, SMAD4, BMPR1A, and LKB1.
Segregation analyses provide strong evidence that B15% of all CRC might be attributable to the action of dominantly acting predisposition genes (Houlston et al., 1992) . Direct evidence for the existence of additional CRC predisposition genes, with moderate penetrance, is provided by families showing evidence against linkage to known loci (Lewis et al., 1996) or segregating novel predisposition loci that are not associated with MMR deficiency, exemplified by CRAC1 (Tomlinson et al., 1999) .
The major genes predisposing to CRC have been identified through linkage analysis. This is the most powerful approach when there is little genetic heterogeneity, penetrance is high and phenocopies are few. The use of conventional genetic linkage to detect genes without these characteristics is more problematic. The risk conferred by the gene may not be sufficient to generate significant familial clustering, and those kindreds that exist may only comprise a small number of affected individuals and hence the power to detect linkage will be small. As a consequence of these theoretical and practical problems, alternative methods of locating disease genes are required.
Most cancer susceptibility genes act as tumorsuppressor or caretaker genes. Loss of tumor-suppressor activity requires inactivating mutations of both alleles of the gene. The event affecting the germ line is generally a minor change in the DNA, such as a single base substitution or small deletion/insertion. The second mutation involving the other allele is often far larger.
This typically involves large stretches of DNA, up to a whole chromosome, and can be detected by loss of heterozygosity (LOH) analysis. Similarly, the presence of an oncogenic predisposition variant may be reflected in amplification of the chromosomal region carrying the germline mutation, exemplified by duplication of chromosomes carrying germline MET mutations in papillary renal cell cancer (Fischer et al., 1998) . Such allelic imbalance (AI), caused by LOH or amplification, can be detected some distance from the gene itself. At a particular susceptibility locus, there may be a higher frequency of AI in familial CRC compared to sporadic forms of the disease. This provides a strategy of identifying susceptibility loci. The approach is solely reliant on the molecular analysis of single cases and it obviates the requirement to collect multiple samples from families. There are some existing data suggesting that this method represents an effective strategy to identify novel cancer susceptibility genes. Prior to the identification of BRCA2, chromosome 13q deletions had been shown to be more common in breast cancers from women with a family history of the disease (Thorlacius et al., 1991) . Clearly, the utility of this approach to the localization of cancer susceptibility genes will be most efficient under homogeneity. The Finnish population provides valuable material for this kind of study. During the centuries the characteristic features of population isolates, founder effect, genetic drift, and isolation have shaped the gene pool of the Finns more homogenous compared, for example, to the populations in central Europe.
We performed a three-step analysis, utilizing microsatellite stable samples to facilitate scoring and to exclude HNPCC patients. Familial cases in all three steps were defined as CRC probands with at least (and typically) one first-degree relative with CRC. In the first phase, we determined the genome-wide allelotypes of the 104 (sample set S1 of 29 familial and 75 sporadic samples, Table 1, Figure 1 ) cases estimating the odds ratio (OR) associated with each marker locus (Figure 2 ). Marker loci showing promise on the basis of at least two adjacent markers displaying a 10% unit difference in AI frequency between familial and nonfamilial cases, and additional three loci that showed near 30% units more AI in the familial group, were selected for step two.
In step one, using a genome-wide panel of 372 markers spaced at B10 cM intervals, we initially profiled 104 CRCs (S1) for AI. Especially frequent AI (losses) were seen on chromosomes 5, 17, and 18, consistent with many previous reports. The fractional allele loss (FAL, in practice a measure of observed allelic losses as well as amplifications because with traditional LOH analysis tools such as microsatellite markers reliably distinguishing the two is difficult) is defined as the fraction of all alleles informatively assayed for each tumor that display AI. Overall the median FAL rate was 0.20 with a range from 0 to 0.55. A significantly higher FAL was associated with distal disease; respective rates 0.10 and 0.23; P ¼ 0.03. No relation between FAL and age was observed (P ¼ 0.46).
ORs and associated 95% confidence intervals (CIs) for the relation between AI and family history were computed for each of the 22 autosome markers. Figure 2 shows crude ORs and CIs for individual marker loci from analysis of the first 104 cases (sample set S1). The frequency of AI was notably greater in familial cases compared to sporadic cases for nine chromosome regions but especially with respect to 7q21.3 defined by D7S657, 14q24.3 defined by D14S74, 20p12.2 defined by D20S186, and 20q13.1-3 defined by D20S178 and D20S171. The most promising regions on the basis of the magnitude of the ORs at each marker and adjacent marker loci were located within chromosome 20 ( Table 2) .
As the second step, an additional 59 familial and 64 sporadic CRCs (sample set S2) were allelotyped at each of the candidate regions as defined above, and the OR associated with each marker was recomputed. To take into account the possible impact of stage or grade on an association, in this and subsequent analyses ORs were adjusted for these covariates. Table 2 shows the results of this analysis. There was no evidence of heterogeneity between the S1 and S2 groups at the 0.05 level of significance. The only consistent relation between AI and family history was seen with the chromosome 20 loci. These markers were chosen for further analysis in step three.
As the third step in the analysis, the three chromosome 20 markers (D20S186 in 20p12.2, D20S178 in 20q13.1, and D20S171 in 20q13.3) were analysed with Table 1 Clinicopathological characteristics of the CRCs analysed Set S1 n=104
Set S2 n=123

Set S3 n=58
Danish set n=42
UK set n=163
Familial n=29 Sporadic n=75 Familial n=59
Sporadic n=64
Familial n=11
Sporadic n=47
Familial n=18 Sporadic n=24 Familial n=67 illustrates an example where a previously presented mathematical model (Canzian et al., 1996) proposed AI (moderate amplification in CGH). (e and f) Marker D20S171 shows an example of a borderline case where the formula did not score for AI. Of note, relative microsatellite marker allele strength as an indicator of amplification may be misleading if, for example, both alleles are amplified. AI analysis was performed in three steps. First, the 104 CRC samples with ample DNA (29 familial and 75 sporadic cases, sample set S1) were analysed with 372 CA-repeat markers (ABI PRISM Linkage Mapping Set MD-10, P/N 450067, 10 cM density, Applied Biosystems (AB) Division, Foster City, CA, USA) To further evaluate the initial findings, the sample set was extended with 59 familial and 64 sporadic cases (sample set S2). Loci were selected for further analyses when the following criteria were fulfilled. The AI percentage at a marker locus was 10 Units or greater (e.g. 20 versus 30% AI cases) in the familial group, and at least one adjacent marker showed such difference as well. From these clusters the locus showing the greatest difference was further analysed. Also, three loci that showed near 30% units more AI in the familial group were included. Third, 47 additional sporadic and 11 familial cases (sample set S3) were analysed with the markers showing significant AI difference after combined analysis of sample sets S1 and S2. S1, S2, and S3 comprised in total 285 CRC samples, 99 of which were familial and 186 sporadic. One locus was further evaluated in CRC samples from Danish (n ¼ 42) and UK (n ¼ 163) populations. All familial cases had at least one first-degree relative affected with CRC. HNPCC, FAP, Juvenile polyposis, and Peutz-Jeghers syndrome cases were excluded (Aaltonen et al., 1998; Salovaara et al., 2000) Allelotype of familial and sporadic colorectal cancers P Laiho et al Allelotype of familial and sporadic colorectal cancers P Laiho et al and sporadic cancers, translating to ORs of between 1.9 and 2.7. A total of 26 familial CRCs were then analysed by comparative genomic hybridization (CGH) to determine whether the chromosomal regions of interest tended to be lost or amplified. Of 26 tumors, 25 showed DNA copy number changes. The most common losses were on 18q, found in 21 out of 26 cases (81%). The minimal overlapping region was 18q22-qter. Other frequent losses involved 14q (39%), 8p (23%), and 4q (23%), Figure 2 Association between family history of CRC and AI at loci on chromosomes 1-22. The relation between AI and family history of CRCs was assessed by means of ORs and associated 95% CIs were obtained through logistic regression. Crude ORs were initially estimated for the S1 sample set. Each box represents the OR point estimate and its area is proportional to the inverse of the variance of each analysis. The horizontal lines represent 95% CI. The unbroken vertical line is at the null value (OR ¼ 1.0). To examine the influence of covariates (grade, site, and age) on ORs in subsequent analyses, stepwise logistic regression was undertaken with a threshold for inclusion/exclusion of a variable of P ¼ 0.1; age was dichotomized into decades. We tested for heterogeneity by comparing the likelihood when all the ORs in each set were assumed to be the same with the likelihood when they were independently estimated. The Mann-Whitney U-test (two-tailed) was used for comparison of unequal sizes and non-normally distributed continuous measures and either the w 2 or Fisher test was used to compare the categorical variables. Other comparisons, such as regression, were undertaken using standard statistical tests. All statistical manipulations were undertaken using the statistical program STATA version 7.0 (Stata Corporation, College Station, TX, USA). We recognize that given the number of comparisons that are being made false associations may be detected. However, correction for multiple testing may inflate type II errors (Perneger, 1998) . Accordingly, we present uncorrected P-values but recognize that our findings are exploratory, requiring confirmation in another case group. This approach minimizes the loss of true-positive findings but does allow false-positive associations to be identified (Cuzick, 1999) with minimal overlapping regions at 14q12-23, 14q24-32, 8p21-pter, and 4q21-qter. The most frequent gains involved 20q (85%), 13q (50%), 7p (39%), 7q (39%), 8q (27%), and 19q (27%), with corresponding minimal overlapping regions at 20q11.2-q12, 13q13-q21, 7p21-pter, 7cen-q21, 8p21-pter, and 8q24.1-qter. High-level copy number increases were found at 19 and 20q. For all three chromosome 20 markers, amplification appeared to be the mechanism underlying AI (Figure 1) . Some CGH studies on unselected/sporadic CRCs have described high proportions of 20q amplifications (Ried et al., 1996; Meijer et al., 1998; De Angelis et al., 1999 Aust et al., 2000) . To examine this aspect we reviewed the literature, and noted that those studies typically had analysed a small number of lesions. We found a total of six studies focusing on unselected/ sporadic CRCs and the number of lesions displaying 20q amplifications was 212 out of 516 (41%) analysed (Ried et al., 1996; Mertens et al., 1997; Meijer et al., 1998; De Angelis et al., 1999 Aust et al., 2000) . The 22 out of 26 or 85% proportion in our set of familial CRCs is highly statistically significantly higher (Po0.0001).
To investigate the relative proportions of both sporadic and familial samples with 20q amplification in our study material, we analysed the 26 familial cases and 26 stage-and sex-matched sporadic cases by quantitative PCR. The 26 sporadic cases were selected blindly to the 20q AI status as evaluated in the genomewide allelotyping. These cases were retrospectively seen to be representative of all sporadic samples in this regard (17 and 20% proportion of AI by microsatellite analysis, respectively). The copy numbers in the tumor samples were determined relative to normal tissue samples from three individuals in the same study group. As reference loci, we used three microsatellite markers (D10S586, D11S1315, D21S1904) from genomic regions that appeared to be relatively stable in our microsatellite study. The relative copy numbers in the CRCs were determined according to Ginzinger et al. (2000) . The copy numbers in the familial group varied from 2 to 5 with a mean value of 3 and in the sporadic group from 1 to 14 with a mean value of 4. Altogether, 72% (18 out of 25) of the familial cases and 73% (19 out of 26) of the sporadic cases were scored as amplified. The cutoff value for amplification was set at 3 because the quantitative PCR analysis can detect single copy changes of a given locus (Ginzinger et al., 2000) . Based on this analysis, there was no difference between the proportion of tumors with amplified 20q in Finnish familial and sporadic CRCs. These observations are intriguing. Whereas quantitative PCR cannot separate between the two alleles and simply emphasizes the importance of 20q amplification in colorectal tumorigenesis, microsatellite marker analysis examines the status of alleles independently. Thus, data combined from the different approaches suggest that while 20q amplification is equally common in Finnish sporadic and familial CRCs, in familial cases the amplification occurs preferentially in one allele. This is reminiscent of the preferential amplification of a mutant oncogenic allele seen in germline MET mutations in papillary renal cell cancer (Fischer et al., 1998) .
The relation between AI at 20q and familial CRC was also examined in two other sample sets from other countries. In a small set of Danish CRC cases, eight out of 10 (80%) informative familial cases showed AI at D20S178 compared with one out of 11 (9%) in sporadic cases (P ¼ 0.002). We then extended the analysis to a larger set of 67 familial and 96 sporadic CRCs from the UK. No significant difference in the frequency of AI at D20S178 was observed between familial and sporadic cases (13/47, 28% and 17/54, 31% informative cases, respectively, P ¼ 0.68). As significant heterogeneity exists between studies, pooling of data was not undertaken.
While multiple studies have examined the allelotype of CRC since 1989 (Vogelstein et al., 1989) , our work is the first to our knowledge to systematically evaluate putative differences between sporadic and familial cases. Our results revealed differences in patterns of AI between Finnish familial and sporadic CRCs. Further- Table 2 Frequency of AI in familial and sporadic CRCs in S1, S1 and S2, and S1 and S2 and S3 sets of samples
Locus
Sample S1 Samples S1+S2 Samples S1+S2+S3 
Pp0.01
Allelotype of familial and sporadic colorectal cancers P Laiho et al more, the data provide some possible insight into the pathogenesis of heritable CRCs outside the context of different polyposis syndromes and MMR deficiency. In this study, we have identified a number of regions of genome that display a higher frequency of AI in familial as compared to sporadic forms of the disease (Figure 2) . The most promising of the regions, which may harbor tumor susceptibility genes, are loci within chromosomes 20p12.2 and 20q13.1-13.3, although the latter location was tested with negative results in a data set representing mixed population. Few genes with obvious functions relevant to a role in colorectal carcinogenesis and/or maintaining genomic stability reside in close proximity to these candidate loci, and possible identification of relevant genes should shed new light on mechanisms of colorectal tumorigenesis. Of note, chromosome 14q that was among the loci selected for further analyses has been reported to be frequently lost in cases with young age of onset (Weber et al., 1999) . Most human cancer susceptibility genes have been identified through genetic linkage. As stated previously, this strategy is optimal in the absence of heterogeneity, if the penetrance or risk ratio is high, phenocopies are few, and large kindreds can be ascertained. There is clear evidence that, for most common cancers, the known genes cannot account for the two to threefold increase in cancer at the same site in first-degree relatives of cases (Peto and Houlston, 2001 ). In addition to highly penetrant genes, there is an increasing indirect evidence for the involvement of gene mutations conferring modest risks. For the reasons stated above, identification of low penetrance susceptibility genes for common cancers is more difficult. It is therefore attractive to adopt complementary approaches to gene identification. One strategy that is frequently considered is allelic association in which a particular allele of a genetic polymorphism is associated with the presence of a disease trait. The underlying assumption is that significant proportion of the disease is caused by a limited number of founder mutations in close proximity to the polymorphism. Generally, such assumptions are unsubstantiated prior to analysis. Furthermore, in addition to technological issues, there are statistical issues relating to the utility of this approach. Specifically, there have been concerns about the extent of linkage disequilibrium across the human genome, suggesting that it may only be detectable at B60 kb (Reich et al., 2001) .
Tumor predisposition loci that lead to an inherited phenotype of multiple premalignant lesions can be detected through allele-specific LOH (Hemminki et al., 1997; Teh et al., 1998) . The utility of this approach will inevitably be highly restricted. Here we have utilized a strategy based on the assumption that mutant germline susceptibility alleles are over-represented in the tumor genome as compared with normal tissue DNA. This strategy may often be hampered because of genetic heterogeneity, but in selected populations may prove to be an important tool because only one normal/tumor sample pair per family is required. Thus, the approach provides an alternative strategy for detecting cancer predisposition genes, which is solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families. The recognition that for most common cancers familial risks are predominantly site specific (Dong and Hemminki, 2001 ) further enhances the utility of this approach.
Allelotyping has primarily been used to investigate the genetic basis of tumor phenotypes per se. Harnessed to epidemiological data, this type of analysis provides an alternative method of mapping and identifying susceptibility genes through comparison of allelotypes in familial and nonfamilial disease. Using this approach, we have shown that differences exist between these two types of disease and have identified loci that potentially harbor novel CRC susceptibility genes, to be evaluated further.
